Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Mar 2 2022 | US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction Industry News In The News Industry Read More Feb 28 2022 | Renovacor Announces Partnerships with the Dilated Cardiomyopathy Foundation, the Heart Failure Society of America and the American Association of Heart Failure Nurses to Help Increase Awareness of Genetic Heart Disorders Industry News Industry Read More Feb 28 2022 | Cytokinetics announces topline results from METEORIC-HF Industry News Industry Read More Feb 28 2022 | Cytokinetics announces start of SEQUOIA-HCM, a phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy Industry News Industry Read More Feb 7 2022 | Cytokinetics announces FDA acceptance of new drug application for omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction Industry News Industry Read More Pagination First page « First Previous page ‹ Previous … Page 8 Page 9 Page 10 Page 11 Current page 12 Page 13 Page 14 Page 15 Page 16 … Next page Next › Last page Last »
Mar 2 2022 | US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction Industry News In The News Industry Read More
Feb 28 2022 | Renovacor Announces Partnerships with the Dilated Cardiomyopathy Foundation, the Heart Failure Society of America and the American Association of Heart Failure Nurses to Help Increase Awareness of Genetic Heart Disorders Industry News Industry Read More
Feb 28 2022 | Cytokinetics announces topline results from METEORIC-HF Industry News Industry Read More
Feb 28 2022 | Cytokinetics announces start of SEQUOIA-HCM, a phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy Industry News Industry Read More
Feb 7 2022 | Cytokinetics announces FDA acceptance of new drug application for omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction Industry News Industry Read More
